How to buy DexCom (DXCM) shares in Australia
Learn how to easily invest in DexCom shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
DexCom Inc (DXCM) is a leading medical devices business with stocks listed in the US. It opened the day at US$445.12 after a previous close of US$446.97. During the day the price has varied from a low of USD436.29 to a high of USD445.49. The latest price was USD440.73 (25 minute delay). DexCom is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in DexCom
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for DexCom. Find the share by name or ticker symbol: DXCM. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DexCom reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$446.97, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of DexCom, depending on your broker.
- Check in on your investment. Congratulations, you own a part of DexCom. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
DexCom stock price (NASDAQ:DXCM)Use our graph to track the performance of DXCM stocks over time.
DexCom shares at a glance
|52-week range||US$318.45 - US$659.45|
|50-day moving average||US$576.8864|
|200-day moving average||US$485.7633|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$5.302|
Where to buy DexCom stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy DexCom stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
DexCom price performance over time
|1 week (2022-01-10)||-4.67%|
|1 month (2021-12-17)||-20.64%|
|3 months (2021-10-15)||-19.05%|
|6 months (2021-07-16)||-1.77%|
|1 year (2021-01-15)||24.43%|
|2 years (2020-01-17)||90.97%|
|3 years (2019-01-17)||194.80%|
|5 years (2017-01-17)||415.53%|
Stocks similar to DexCom
Is DexCom under- or over-valued?
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's P/E ratio
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 89x. In other words, DexCom shares trade at around 89x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's PEG ratio
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.9111. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$447.1 million (£0.0 million).
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$2.3 billion|
|Operating margin TTM||15.92%|
|Gross profit TTM||US$1.3 billion|
|Return on assets TTM||5.36%|
|Return on equity TTM||29.12%|
|Market capitalisation||US$45.7 billion|
TTM: trailing 12 months
DexCom's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
DexCom's total ESG risk score
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
DexCom's environmental score
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
DexCom's social score
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
DexCom's governance score
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
DexCom's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.18|
|Total ESG percentile||50.12|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
DexCom share dividends
We're not expecting DexCom to pay a dividend over the next 12 months.
DexCom share price volatility
Over the last 12 months, DexCom's shares have ranged in value from as little as US$318.45 up to US$659.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 0.7572. This would suggest that DexCom's shares are less volatile than average (for this exchange).
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
DexCom in the news
Got $5,000? 2 Top Growth Stocks to Buy and Hold for Decades
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Frequently asked questions
More guides on Finder
Interview: RAQ founder talks Abbie Chatfield swim collection
RAQ Apparel founder Sophia Argyropoulos chats the inspo for Abbie Chatfield swimwear collab and the secret to finding the perfect bikini.
7 ways to elevate your home movie experience [SPONSORED] Turn your low-key movie nights into a main attraction that can keep everyone entertained.
American Express Qantas Corporate Gold Card
With a 100,000 bonus Membership Rewards offer and complimentary Qantas Business Rewards membership, is this the right card for your business?
How to watch Liverpool vs Arsenal Carabao Cup live and free in Australia
Liverpool and Arsenal battle for a place in the League Cup final.
Rapid antigen tests: When will RAT stock be available? [UPDATED]
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
New on Netflix, Prime Video, Disney Plus, Stan, Foxtel, BINGE and more in January 2022
You can easily elevate your binge-watching game in the New Year.
Where to watch DC series Peacemaker online in Australia
He believes in peace at any cost – no matter how many people he has to kill to get it.
How to watch Melbourne Renegades vs Melbourne Stars BBL live and match preview
Both Melbourne teams are fighting for their seasons as we embark on derby number 2
10 beauty trends that’ll pop off in 2022
From clean beauty to bedazzled everything, these are the makeup looks will take over 2022 and the products you need to pull them off.
Compare rapid antigen test brands: How do they stack up?
Not all tests are created equal here are the different brands compared.
Ask an Expert